A team of scientists from the Chinese Academy of Sciences has discovered how a traditional Chinese medicinal plant, known as Tripterygium wilfordii, produces an anti-cancer compound called triptolide. The findings, published in the journal Nature Communications, could lead to the development of new cancer treatments.

Triptolide has been shown to have a variety of anti-cancer effects, including inhibiting the growth of cancer cells, promoting cell death, and reducing inflammation. However, the exact mechanism by which triptolide exerts its effects has been unclear.

In the new study, the researchers used a combination of techniques, including gene expression analysis, metabolomics, and molecular docking, to identify the key enzymes and metabolic pathways involved in triptolide biosynthesis. They found that triptolide is produced through a complex cascade of reactions, involving multiple enzymes and intermediates.

The researchers also identified a key regulator of triptolide biosynthesis, a transcription factor called MYB4. MYB4 is responsible for controlling the expression of genes involved in triptolide biosynthesis. By manipulating the expression of MYB4, the researchers were able to increase or decrease the production of triptolide in Tripterygium wilfordii.

The findings of this study provide new insights into the biosynthesis of triptolide and could lead to the development of strategies to increase the production of this anti-cancer compound in Tripterygium wilfordii. This could make triptolide more accessible for use in cancer treatments.

Triptolide is a promising anti-cancer compound, but its clinical use has been limited due to its toxicity. The researchers hope that their findings will lead to the development of new, less toxic triptolide derivatives that can be used to treat cancer more effectively.